iCreatAI News
Skip to content
Trending storyUpdating

Isomorphic Labs completes $5 billion Series C funding

2 reports2 sources10 hr agoUpdated

Understand this story

AI overview

Isomorphic Labs, the AI drug discovery company spun out of DeepMind, has completed a $5 billion Series C funding round, co-led by Greenoaks and Sequoia Capital, with participation from new investors including Andreessen Horowitz, and all existing investors such as Alphabet's GV and Capital G following on. The company said the funding will be used to advance candidate drugs into clinical trials. The Decoder reported that this is Isomorphic Labs' second funding round completed within six months.

AI overview based on source reports · Updated 8 hr ago

Coverage timeline

Follow the coverage to explore different perspectives.

Nov 17
  1. The Decoder
    Isomorphic Labs raises $5 billion in its second mega-round within six months

    Alphabet's AI drug discovery company Isomorphic Labs has raised $5 billion, its second billion-dollar round in six months, co-led by Greenoaks and Sequoia Capital with new backer Andreessen Horowitz, Alphabet and all existing investors. The company had already raised $2.1 billion in May 2026, and the money will go toward advancing its in-house IsoDDE platform and pushing its drug pipeline toward clinical trials. Isomorphic Labs works with Novartis, Eli Lilly and Johnson & Johnson but has no approved drug yet.

  2. TechCrunch · AI
    Isomorphic Labs raises $5B as it looks to take drug candidates to clinical trials

    Isomorphic Labs, the AI drug-discovery platform spun out of Google's DeepMind in 2021, has raised $5 billion in a Series C round co-led by Greenoaks and Sequoia Capital, with Andreessen Horowitz and all existing backers also participating. The company said its AI drug-design engine, built on DeepMind's AlphaFold work, has yielded "positive preclinical results" in oncology and immunology, and it has struck deals with Eli Lilly, Novartis, and Johnson & Johnson. The funding, following a $2.1 billion Series B in May, will go toward developing its drug-design engine and expanding into more types of medicine; Isomorphic did not disclose its new valuation.

Activity for this story

Current comparable activity
15
Peak comparable activity
19Nov 18 00:00
Change in the past 24 hours
–

Trends compare the same fully observed participants, which may cover fewer participants than current activity. Move the pointer or tap the chart to inspect hourly activity; use the left and right arrow keys with a keyboard.